Steve Jenison is an accomplished inventor based in Albuquerque, NM (US). He has made significant contributions to the field of molecular biology, particularly in the development of recombinant DNA antigens related to hantaviruses. With a total of 2 patents, his work has implications for immunodiagnostics and therapeutics.

Latest Patents

Jenison's latest patents include innovations that focus on the hantavirus-associated respiratory distress syndrome (HARDS). The first patent, titled "Molecular clones producing recombinant DNA antigens of the hantavirus-associated respiratory distress (HARDS)," provides HARDS virus rDNA for expression in molecular clones. The expressed products are useful in immunodiagnostics, prophylactics, and therapeutics for the HARDS virus and related hantaviruses. Of particular interest are a type-specific epitope of the HARDS virus G1 protein and dominant epitopes of the HARDS virus N protein, which are cross-reactive with antibodies to the HARDS virus and the related hantavirus PHV. Both of these are expressed by cDNA clones according to the invention.

The second patent, "Hantavirus-associated respiratory distress virus antigens," similarly provides HARDS virus rDNA for expression in molecular clones. This invention also emphasizes the utility of the expressed products in immunodiagnostics, prophylactics, and therapeutics for the HARDS virus and related hantaviruses.

Career Highlights

Steve Jenison is affiliated with the University of New Mexico, where he continues to advance research in the field of virology. His work has garnered attention for its potential to improve diagnostic and therapeutic strategies against hantavirus infections.

Conclusion

Steve Jenison's innovative contributions to hantavirus research highlight the importance of molecular biology in addressing public health challenges. His patents pave the way for advancements in immunodiagnostics and therapeutics, showcasing the impact of his work in the scientific community.